-
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Analog insulin detemir for patients with type 1 and type 2 diabetes: a review
Review
(3432) Views (847) Full article downloads
Authors: Gregory E Peterson
Published Date May 2009
Volume 2009:2 Pages 31 - 36
DOI: http://dx.doi.org/10.2147/DMSO.S3401
Gregory E Peterson
Department of Internal Medicine, Des Moines University, USA
Objective: To review insulin detemir for clinical use to better manage patients with type 1 and type 2 diabetes.
Methods: A MEDLINE search, in English, from June 30, 2006 to December 1, 2008, using the terms “insulin analogs,” “insulin detemir” and “long-acting insulin analog.”
Results: Insulin detemir improves glycemic control, based on HbA1C reduction and fasting glucose levels, without increasing the risk of hypoglycemia and weight gain. Insulin detemir has lower glycemic variability, with less intra-subject variability in blood glucose levels in patients with type 1 and type 2 diabetes, without increasing the risk of hypoglycemia. When added to oral anti-diabetes agents (OADs) in type 2 diabetes, insulin detemir demonstrates superiority to other basal insulin options.
Conclusion: Insulin detemir appears to provide better glycemic control with a lower risk of hypoglycemia and less weight gain in the treatment of patients with type 1 and type 2 diabetes.
Keywords: type 1 diabetes, type 2 diabetes, insulin analogs, insulin detemir
Readers of this article also read:
Changing basal insulin from NPH to detemir or glargine in patients with type 1 diabetes and a history of severe hypoglycemia
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Risk management in the treatment of type 2 diabetes with pioglitazone
Self-monitoring of blood glucose in noninsulin-treated type 2 diabetes: an overview
Amantadine reduces glucagon and enhances insulin secretion throughout the oral glucose tolerance test: central plus peripheral nervous system mechanisms
Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus
An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog
Pioglitazone for the treatment of type 2 diabetes in patients inadequately controlled on insulin
Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
- Testimonials
"You do a tremendous job!!" Ruben Restrepo, The University of Texas Health Science Center at San Antonio
- The economic impact of obesity in the United States
- Alogliptin: a new addition to the class of DPP-4 inhibitors
- Self-monitoring of blood glucose in noninsulin-treated type 2 diabetes: an overview
- Adipose inflammation: cause or consequence of obesity-related insulin resistance




